Healthcare-associated
infections (HAIs) remain an important source of morbidity and mortality with an
estimated 1.7 million infections and 99,000 deaths annually. A major source of
nosocomial pathogens is thought to be the patient’s endogenous flora, but an
estimated 20-40% of healthcare-associated infections have been attributed to
cross-infection via the hands of healthcare personnel. Contamination of the hands of healthcare
personnel could in turn result from either direct patient contact or indirectly
from touching contaminated environmental surfaces. Healthcare personnel have
frequent contact with the environmental surfaces in patients’ rooms providing
ample opportunity for contamination of gloves and/or hands. Two recent studies demonstrated that contact
with the environment was just as likely to contaminate the hands of healthcare
workers as was direct contact with the patient. Donskey has reviewed the scientific literature
and found that improving surface cleaning and disinfection reduces
healthcare-associated infections (Am J Infect Control 2013: 41:S12-S19). Another recent paper showed that daily
disinfection of surfaces (versus standard cleaning surfaces when visibly
soiled) with a sporicidal disinfectant in rooms of patients with Clostridium difficile and methicillin-resistant Staphylococcus aureus (MRSA) reduced
acquisition of pathogens on gloved hands after contact with room surfaces. While disinfectants are used to prevent transmission
of pathogens from both noncritical and semicritical items, the purpose of this
brief article is to assist the user in the selection of the optimal
disinfectant for use with environmental
surfaces and noncritical patient care items (devices that contact only intact skin
such as stethoscopes). The same
characteristics for an ideal low-level disinfectant would be used for
high-level disinfectants; however, the contact time would be longer and
antimicrobial spectrum would be broader (e.g., may include C. difficile spores). To
date, the perfect product for healthcare disinfection has not been introduced;
however, there is a wide array of disinfectants that offer a range of
characteristics.
News and research from North Carolina infection control and prevention experts
Tuesday, March 25, 2014
Review of New and Current ACIP Recommendations
by David J. Weber, MD, MPH
Vaccines
recommended for susceptible HCP include the following:
·
Mumps
(2 doses): MMR preferred (assume immune
if born before 1957 except during an outbreak)
·
Measles
(2 doses): MMR preferred (assume immune
if born before 1957 except during an outbreak)
·
Rubella
(1 dose): MMR preferred (indicated for
all female HCP of childbearing potential)
·
Influenza
(1 dose yearly)
·
Varicella
(2 doses)
·
Tetanus
toxoid, diphtheria toxoid, pertussis (1 dose of Tdap)
·
Hepatitis
B (3 doses with quantitative anti-HBsAg titer 1-2 months after 3rd
dose): Indicated for HCP who have
potential exposure to blood or contaminated body fluids.
·
Meningococcal
vaccine (1 dose; booster every 5 years if risk continues): Indicated for lab personnel who spin cerebrospinal
fluid.
New
changes in the vaccine schedule relevant to HCP include:
·
Recombinant
influenza vaccine (RIV) or inactivated influenza vaccine (IIV) can used among
HCP with hives-only allergy to eggs. RIV
contains no egg protein and can be used among persons aged 18 to 49 years who
have egg allergy of any severity.
·
A
single dose of Tdap vaccine is recommended for HCP; a Td booster should be
administered every 10 years thereafter.
Public Reporting of MRSA and Clostridium difficile LabID Events
by Zack Moore, MD and Jennifer MacFarquhar, RN, MPH, CIC
Clostridium difficile (C. diff) and methicillin-resistant Staphylococcus aureus (MRSA) are both important public health problems, responsible for approximately 14,000 and 11,000 deaths in the United States each year, respectively. Both of these infections are frequently acquired in healthcare settings and have therefore been the target of many control efforts by hospitals working independently and in collaboration. These efforts have led to a 54% reduction in the number of invasive MRSA infections occurring during hospitalization between 2005 and 2011.1 However, the incidence of C. diff infections has continued to increase in recent years, as has the number of deaths attributed to C. diff in North Carolina.2,3
Beginning in January
2013, all acute care hospitals in North Carolina began reporting MRSA
bacteremia and C. diff LabID events through the CDC’s National Healthcare
Safety Network (NHSN). These
hospital-specific data were first made public on the Centers for Medicare and
Medicaid Services’ Hospital Compare website beginning in December 2013 and were
first included in the North Carolina Division of Public Health’s Healthcare-Associated
Infections Quarterly Report in January 2014.4,5
LabID event reporting
is based solely on laboratory results, and therefore some of the events
reported may not represent true infections. However, this method of reporting
has the advantages of being relatively more objective and less labor-intensive
than case-based reporting using clinical case definitions. Moreover, publication of these infection data provides an
opportunity to examine and understand the information on a statewide and
individual hospital level. In North Carolina, infection rates for the first
nine months since reporting began (January–September 2013) were within the
predicted range for both C. difficile
and MRSA bacteremia. Data from the first full year of reporting will be
published in the upcoming annual report, anticipated in April 2014.
No Foolin’! SPICE rolls out new educational offerings
Also, on April 1st, SPICE will launch its newly
revised Curriculum for Infection Control in Dental Settings. The course is
offered through the SPICEducation website for $150 (go to
spiceducation.unc.edu), as well as through approved providers in classroom and
webinar formats (more information at spice.unc.edu/dental).
Friday, March 14, 2014
National Action Plan to Prevent Healthcare-Associated Infections Current Progress and Proposed Targets for 2020
The U.S. Department of Health and Human
Services released proposed targets and metrics for the National Action Plan to
Prevent Healthcare-Associated Infections, as virtually all of the previous
targets and metrics expired December 2013.
A
national stakeholder meeting was held in September 2013 and helped shape the
proposed targets along with a federal steering committee of HAI prevention
experts from federal agencies.
The
proposed targets would set 2015 as the new baseline, with the exception of
invasive MRSA, which was included in the federal government’s Healthy People
2020 goals and has an existing 2007-2008 baseline, which has not expired.
This
table outlines the proposed new targets for 2020, alongside the most recent
progress on the measures to date. The proposed metrics can also be viewed here.
CDC Vital Signs: Antibiotic Prescribing in Hospitals
CDC’s March VitalSigns highlighted
the effect poor prescribing habits can have on the ability to protect patients
from unnecessary risk and preserve the power of antibiotics. The report found that approximately one-third of the
time, prescribing practices to treat urinary tract infections and prescriptions
for vancomycin
included a potential error – given without proper testing or evaluation, or
given for too long. In addition to the potential errors, prescribing practices
vary widely between hospitals and doctors within a hospital. According to CDC,
doctors in some hospitals prescribed 3 times as many antibiotics as doctors in
other hospitals.
CDC
estimates that reducing the use of high-risk antibiotics by 30% can lower C.
difficile
infections
by 26%. CDC recommends that hospitals have an antibiotic stewardship program in
place to reduce instances of inappropriate antibiotic prescribing.
The
release of the March Vital Signs coincides
with CDC’s announcement of a new antibiotic resistance initiative, that will
focus on the four core actions called for in CDC’s Antibiotic Resistance Threat
Report: detection of antibiotic resistance; response to outbreaks; prevention
of infections; discovery of new antibiotics and diagnostic tests for
resistance. The initiative aims to reduce the threats of seven antibiotic
resistant organisms, including carbapenem-resistant
Enterobacteriaceae
(CRE), by improving detection through regional laboratories and strengthening
antibiotic prescribing practices.
CDC recommends that hospitals
institute an antibiotic stewardship program that includes:
•Leadership
commitment
•Accountability
•Drug
expertise
•Taking
at least one prescribing improvement
action
•Tracking
prescribing and antibiotic resistance patterns
•Regularly
reporting to staff prescribing and antibiotic resistance patterns
•Education
CDC Unveils New Website to Improve Infection Control Practices in Long-Term Care Facilities
The Centers for Disease Control and Prevention (CDC) announced the launch of a new website with infection prevention resources for long-term care settings such
as nursing homes and assisted living. This site organizes existing
infection prevention guidance and resources into sections for clinical
staff, infection prevention coordinators, and residents.
Facilities can also directly access the new infection tracking system for long-term care facilities in CDC’s National Healthcare Safety Network, and the innovative infection prevention tools and resources developed as part of the partnership between CDC and the Advancing Excellence in America’s Nursing Homes Campaign (AE).
On the CDC’s Safe Healthcare blog, Nimalie Stone, MD, medical epidemiologist and long-term care expert at CDC, discusses this new website, including the resources developed under the partnership between CDC and Advancing Excellence to prevent C. difficile infections in nursing home residents.
Facilities can also directly access the new infection tracking system for long-term care facilities in CDC’s National Healthcare Safety Network, and the innovative infection prevention tools and resources developed as part of the partnership between CDC and the Advancing Excellence in America’s Nursing Homes Campaign (AE).
On the CDC’s Safe Healthcare blog, Nimalie Stone, MD, medical epidemiologist and long-term care expert at CDC, discusses this new website, including the resources developed under the partnership between CDC and Advancing Excellence to prevent C. difficile infections in nursing home residents.
Thursday, November 21, 2013
Case of CJD Disease in New Hampshire
In September 2013, health officials confirmed that a patient
who underwent neurosurgery at a New Hampshire hospital earlier in the year had
Creutzfeldt-Jacob disease. The death,
and suspicions that the patient may have had the devastating brain ailment,
prompted authorities in two states to warn that as many as 13 patients may have
been exposed to surgical equipment used during the patient's surgery, thus to
the same disease. The now-deceased patient had undergone neurosurgery at a New
Hampshire hospital and the patient was later suspected of having sporadic Creutzfeldt-Jakob disease, a rare, rapidly progressing and always-fatal degenerative brain
disease. But by the time this diagnosis was suspected, equipment used in the
patient's surgery had been used several other operations. This raised the
possibility that the equipment might have been contaminated -- especially since
normal sterilization procedures are not enough to get rid of the disease
proteins, known as prions, tied to Creutzfeldt-Jakob disease -- thus
potentially exposing the other patients to infection (Botelho, CNN, September
2013). This exposure scenario could
happen in any hospital and this is why we must remain vigilant and implement
practices that minimize its occurrence in our hospitals.
Creutzfeldt-Jakob
disease (CJD) is a degenerative neurologic disorder of humans with an incidence
in the United States of approximately 1 case per million population per year. CJD is caused by a proteinaceous
infectious agent, or prion. Prion
diseases elicit no immune response, result in a
noninflammatory pathologic process confined to the central nervous system, have
an incubation period of years, and usually are fatal within 1 year after diagnosis.
Subscribe to:
Posts (Atom)